[1]马少君a,樊民义a,康晓丽a,等.乳腺癌组织雄激素受体表达与临床相关病理特征分析[J].现代检验医学杂志,2019,34(06):36-40.[doi:10.3969 ／ j.issn.1671-7414.2019.06.009]
　MA Shao-juna,FAN Min-yia,KANG Xiao-lia,et al.Analysis of Androgen Receptor Expression and Clinical Pathological Features in Breast Cancer Patients[J].Journal of Modern Laboratory Medicine,2019,34(06):36-40.[doi:10.3969 ／ j.issn.1671-7414.2019.06.009]
点击复制

乳腺癌组织雄激素受体表达与临床相关病理特征分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年06期
页码:
36-40
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Analysis of Androgen Receptor Expression and Clinical Pathological Features in Breast Cancer Patients
文章编号:
1671-7414（2019）06-036-05
作者:
马少君a; 樊民义a; 康晓丽a; 樊国峰a; 周理乾a; 李文生b
（陕西省人民医院 a. 放射科；b. 病理科，西安　710068）
Author(s):
MA Shao-juna ;  FAN Min-yia; KANG Xiao-lia; FAN Guo-fenga;  ZHOU Li-qiana;  LI Wen-shengb
（a.Department of Radiology; b. Department of Pathology, Shaanxi Provincial People’s Hospital ，Xi’an 710068， China）
关键词:
乳腺癌; 雄激素受体 ;  临床病理特征; 预后
分类号:
R737.9; R730.43　
DOI:
10.3969 ／ j.issn.1671-7414.2019.06.009
文献标志码:
A
摘要:
目的　分析乳腺癌患者组织雄激素受体（androgen receptor，AR）表达状况, 并探讨其与常见的组织病理学参数 及预后的相关性。方法　选取2012~2016 年经病理确诊的190 例乳腺癌患者肿瘤组织标本，通过免疫组织化学方法(IHC) 检测肿瘤组织AR 蛋白水平, 分析AR 表达与不同临床病理参数及预后的相关性 。结果　190 例乳腺癌组织中AR 阳性 表达率为80.0%，44 例三阴型乳腺癌（TNBC）患者AR 阳性表达率为33%；Ⅰ级和Ⅱ级组织学分级乳腺癌中 AR 阳性 表达率84.5%，Ⅲ级组织学分级AR 阳性表达率为66.7%，AR 阳性乳腺癌多对应较低组织学分级，AR 表达与组织学分 级呈负相关（χ2=7.136, P <0.01）；雌激素受体（estrogen receptor, ER）阴性乳腺癌 AR 阳性表达率为 60.6%，ER 阳性乳 腺癌 AR 阳性表达率为 90.3%。孕激素受体（progesterone receoptor, PR）阴性乳腺癌 AR 阳性表达率为 65.9%，PR 阳性 乳腺癌 AR 阳性表达率为 90.7%，AR 表达与ER 表达、PR 表达呈正相关（χ2 =23.773, P <0.001；χ2 =18.043, P <0.001）； Ki- 67<14% 组乳腺癌AR 阳性表达率90.3%，Ki- 67 ≥ 14% 组乳腺癌AR 阳性表达率75.4%，AR 表达与Ki-67 指数呈 负相关（χ2 =5.481, P <0.05）；AR 表达在非三阴型乳腺癌（Non-TNBC）与三阴型乳腺癌（TNBC）的差异有统计学意义（χ2 =32.209，P <0.001）；AR 阳性的乳腺癌患者的总生存期明显高于AR 阴性者（P <0.05）；AR 表达在患者年龄、月经状态、 肿瘤大小、腋窝淋巴结、HER-2 及血管浸润差异无统计学意义（χ2=0.022~3.558，均P >0.05）。结论　AR 表达与多种 临床病理因素存在相关性，AR 可能是乳腺癌的预测指标及预后重要因素。
Abstract:
Objective　To detect of expression and analyse associations with common histopathological parameters in breast cancer cases and clinical outcome. Methods　190 breast spcimens were obtained breast cancer-cases confirmed by pathological diagnosis from 2012 to 2016, and formalin-fixed，paraffin –embedded samples of tumors were tested by immunohistochemistry (IHC) as a primary estimate of AR status, and evaluated the correlation between AR expression status and different clinical pathologi-cal features and clinical outcome. Results　The positive expression of AR in breast cancer was 80.0%, the positive expression of AR in TNBC was 37%. The positive expression of AR was 84.5% in grade Ⅰ and grade Ⅱ breast cancer, and 66.7% in grade Ⅲ. This positive expression of AR cases mostly exhibited a lower Histological grade(χ2 =7.136, P <0.01), AR expression was inversely correlated to histological grade. The positive expression of AR was 60.6% in ER negative breast cancer versus 90.3% in ER positive breast cancer, and 65.9% in PR negative breast cancer versus 90.7% in PR positive breast cancer， AR expression was positively inverse associated with expression of hormone receptors (ER and PR) among the patients studied, AR positive expression was corresponds to ER positive expression and PR positive expressions（χ2=23.773, P <0.001；χ2 =18.043, P <0.001）. The positive expression of AR was 90.3% in breast cancer of Ki- 67<14% group，while the positive expression of AR was 90.3% in breast cancer of Ki- 67 ≥ 14% group，and AR expression was inversely correlated to Ki-67 expression（χ2 =5.481, P <0.05）. The expression of AR were significant differences in Non-TNBC with TNBC（χ2 =32.209, P <0.001）,and the overall survival (OS ) of AR positive expression patients was significantly higher than AR negative expression patients（P <0.05）.The expression of AR were significant differences in age, menopausal status , tumor size，axillary lymph node，HER-2，Vascular invasion（χ2=0.022~3.558, all P >0.05）. Conclusion　There had correlation of many clinical factors with AR expression. AR may be an indicator to predict breast cancer and prognostic factor for breast cancer.

参考文献/References:

[1]　CHEN Wangqing，ZHANG Rongshu，BAADE P D, et a1．Cancer statistics in China 2015[J]．CA: A Cancer J Clin，2016,66（2）：115-132.
[2]　RAVDIN P M,SIMINOFF P M,DAVIS G J,et a1. Computer program to assist in making decisions about adjujvant therapy for women with early breast cancer[J]. J Clin Oneol，201l，19(4)：980-991．
[3]　HULKA B S,MOORMAN P G. Breast cancer:hormones and other risk factors[J]. Maturitas,2015，38(2):103- 113: discussion 113-116.
[4]　COBLEIGH M A,VOGEL C L, TRIPATHY D, et a1. Mul-tinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease[J].J Clin Oncol, 2013，17(9):2639- 2648.
[5]　LUMACHI F,LUISETTO G, BASSO SMM, et a1. Endocrine therapy of breast cancer[J]. Curr Med Chem.2011，18(4):513-522.
[6]　GAO Wenqing, BOHL C E,DALTON J T, et a1. Chemistry and structural biology of androgen receptor[J]. Chem Rev, 2005,105(9):3352-3370.
[7]　HEEMERS H V,TINDALL D J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex[J]. Endocr Rev, 2017,28(7):778-808.
[8]　HU Rong, DAWOOD S,HOLEMS M D, et a1. Androgen receptor expression and breast cancer survival in postmenopausal women[J].Clin Cancer Res,2011,17(7):1867-1874.
[9]　DE’AMICIS F, THIRUGNAN SAM PANTHAN J, CUI Yukun, et a1. Androgen receptor overexpres-sion induces tamoxifen resistance in human breast cancer cells[J]. Breast Cancer Res Treat, 2010,121(1):1-11.
[10] MOINTAR F,OKCU M, TSYBROVSKY O, et a1. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies[J]. Cancer. 2003,98(4):703-711.
[11] PETERS K M,EDWARDS S L, NAIR S S, et a1. Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events[J]. BMC Cancer, 2012,12:132.
[12] SOREIDE J A,LEA O A, VARHAUG J E, et a1.Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treat-ment[J]. Eur J Surg Oncol, 2012,18(2): 112-118.
[13] PARK S Y, KOO J S, KIM M S, et a1. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers[J]. Ann Oncol, 2011,22(8):1755-1762.
[14] QU Qing, MAO Yan, FEI Xiaochun, et a1. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis[J]. PLoS One, 2013, 8(12): e82650.
[15] TOKUNAGA A E,HISAMATSU Y,TAKETANI K, et a1. Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer[J]. Cancer Med. 2013, 2(6):763-773.
[16] HE Bin, BAI Suxia, HNAT A T, et a1．An androgen receptor NH2·terminal congelved motif interacts with the COOH terminus of the Hsp70-interacting protein(CHIP) [J]．J Biol Chem，2014，279(29)： 30643-30653．
[17] KAMAL A，THAN L，SEIVSINTAFFAR J，et a1． A hish-affinity conformation of Hsp 90 confers tumour selectivity oil Hsp90 inhibitors[J]．Nature，2003， 425(6956)：407-410．
[18] NIELSEN T O,HSU F D,JENSEN K, et a1． Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma[J]．Clin. Cancer Res. 2014,10(16)：5367-5374.
[19] PEROU C M． Molecular stratification of triplenegative breast cancers[J]. Oncologist 2011,16(suppl 1)：61-70.
[20] BAUER C,PEIGNE V,GISSELBRECHT M, et a1． Unusual presentation of myeloma in an elderly woman: Breast and cutaneous involvement[J]. Eur J Intern Med, 2018, 19(2)：150-151.
[21] 高仁里, 张丹, 叶慧英, 等. 乳腺癌中雄激素受体的 表达及与雌激素、孕激素受体表达的关系[J]. 标记 免疫分析与临床,2015,22(11):1073-1076. GAO Renli, ZHANG Dan,YE Huiying, et a1．The relationship between androgen receptor expression with estrogen and progesterone receptor in breast carcinoma [J]. Labeled Immunoassays and Clinical Medicine,2015,22(11):1073-1076.
[22] 屠世晔 , 王波 , 毛海波, 等. 雄激素受体在乳腺癌不 同分子分型中的表达差异[J]. 浙江实用医学 , 2016, 21(2): 94-97. TU Shiye, WANG Bo, MAO Haibo， et a1． Expression difference of androgen receptor in different molecular types of breast cancer [J]. Zhejiang Practical Medicine，2016, 21(2): 94-97.
[23] RIVA C，DAINESE E，CAPRARA G，et a1． Immunohistochemical study of androgen receptors in breast carcinoma．Evidence of their frequent expression in lubrlar carcinoma [J].．Virchows Arch， 2005，447(4)：695-700．
[24] OGAWA Y，HAI Eishu，MATSUMOTO K ，et al. Androgen receptor expression in breast cancer： relationship with clinicopathological factors and biomarkers [J]. Intermational Journal of Clinical Oncology, 2008,13（5）：431-435.
[25] QI Jiping, YANG Youlin, ZHU Hong. Expression of the androgen receptor and its correlation with molecular subtypes in 980 Chinese breast cancer patients [J]. Breast Cancer, 2012，6（1）：1-8．
[26] 李瑞亮，周涛，周冰峰，等．原发性乳腺癌组织中 雄激素受体的表达及其与临床病理指标的关系[J]． 肿瘤防治研究，2012,39(3)：292-294． LI Ruiliang, ZHOU Tao, ZHOU Bingfeng, et al. Androgen receptor expression in primary breast cancer and its relationship with clinicopathological factors[J]. Cancer Research on Prevention and Treatmen, 2012,39(3) : 292-294.
[27] LUMACHI F,LUISETTO G, BASSO SMM, et al. Endocrine therapy of breast cancer[J]. Curr Med Chem, 2011,18(4):513-522.
[28] TOKUNAGA E,HISAMATSU Y,TAKERTANI K, et al. Differential impact of the expression of the androgen receptor by age in estrogen receptor–positive breast cancer[J]. Cancer Med, 2013,2(6):763-773.
[29] SAMAKA R M,YOUNES S F. Androgen receptor expression in breast carcinoma of egyptian patients[J]. J Clin Diagn Res.2016,10(11):EC17.-ECD21.

相似文献/References:

[1]党小军,张华,王欣.人附睾蛋白4(HE4)在乳腺癌诊断中的价值[J].现代检验医学杂志,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
　DANG Xiao-jun,ZHANG Hua,WANG Xin.Value of Human Epididymis Protein 4(HE4) in Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
[2]张 萍,任世云,张 雷.乳腺癌患者血清脂质运载蛋白-2 和基质金属蛋白酶-9的表达及临床意义[J].现代检验医学杂志,2015,30(01):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
　ZHANG Ping,REN Shi-yun,ZHANG Lei.Expression and Clinical Significance of Serum LCN-2 and MMP-9 in Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
[3]乔雪峰a,黄志平b,张 宁c,等.IL-18基因启动子区-137G/C,-607G/T 2个位点基因多态性与女性乳腺癌易感性Meta分析[J].现代检验医学杂志,2016,31(04):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
　QIAO Xue-fenga,HUANG Zhi-pingb,ZHANG Ningc,et al.Association Analysis of IL-18 Gene Promoter Region -137G/C,-607G/T Polymorphisms and Susceptibility to Sporadic Breast Cancer:Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(06):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
[4]刘延梅,马少君,张月浪,等.人类表皮生长因子受体2在乳腺癌表达与临床的相关病理特征分析[J].现代检验医学杂志,2016,31(05):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
　LIU Yan-mei,MA Shao-jun,ZHANG Yue-lang,et al.Expression of Human Epidermal Growth Factor Receptor 2 and Correlation with Clinical Pathological Features in Breast Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
[5]陈雨欣,谭婷婷,宁明哲.乳腺癌患者血清中白介素35(IL-35)的表达及其临床意义[J].现代检验医学杂志,2017,32(02):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
　CHEN Yu-xin,TAN Ting-ting,NING Ming-zhe.Serological Interleukin-35 Level in Patients with Breast Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(06):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
[6]唐努尔·艾尔肯,阿孜古·祖农.盐酸罗哌卡因对人乳腺癌细胞运动作用的研究[J].现代检验医学杂志,2017,32(03):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
　TANGNUER·Aierken,AZIGU·Zunong.Study on Effect of Ropivacaine on Migration of Breast Cancer Cell s[J].Journal of Modern Laboratory Medicine,2017,32(06):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
[7]靳庆娥,苏建荣.北京地区汉族女性人群SYK基因启动子区-803A>Trs290987单核苷酸多态性与乳腺癌易感性分析[J].现代检验医学杂志,2018,33(02):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　JIN Qing-e,SU Jian-rong.Associations of SYK Promoter-803A >T(rs290987)Single Nucleotide Polymorphisms with Susceptibility to Breast Cancer of Han Female Population in Beijing Area[J].Journal of Modern Laboratory Medicine,2018,33(06):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]高 华a,李玉柱b,韩龙才c,等.Logistic回归和ROC工作曲线评价联合检测血清CA153,TPS,CYFRA21-1在乳腺癌诊断中的临床价值[J].现代检验医学杂志,2018,33(03):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
　GAO Huaa,LI Yu-zhub,HAN Long-caic,et al.Clinical Value of Logistic Regression and ROC Work Curve Evaluating Serum CA153,TPS and Cyfra21-1 for Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
[9]李 娜a,赵晓娟b,苏晓明a.乳腺组织中SMG-1mRNA和SOX4mRNA检测在乳腺癌监测中的应用[J].现代检验医学杂志,2019,34(02):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
　LI Naa,ZHAO Xiao-juanb,SU Xiao-minga.Application of Detection of SMG-1mRNA and SOX4mRNAin Breast Tissue in Surveillance for Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
[10]王 碧,吉茂礼.乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究[J].现代检验医学杂志,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
　WANG Bi,JI Mao-li.Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(06):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]

备注/Memo

备注/Memo:
基金项目：西安市科技计划项目[ 编号：2017117SF ／ YX011（4）]；陕西社发科技攻关项目( 编号：2016SF-168) 。 作者简介：马少君（1975-），男，副主任医师，从事乳腺疾病、骨关节及消化道疾病影像诊断。 通讯作者：樊民义（1969-），男，主治医师，从事乳腺疾病、骨关节及消化道疾病影像诊断。收稿日期：2019-10-15
更新日期/Last Update: 2019-12-25